Table 1.
Effect of 17-AAG on motility parameters in human sperm
| DMSO | 5 µM 17-AAG | |
|---|---|---|
| Motility (%) | 62.5 ± 8.5 | 51.4 ± 2.9 |
| VSL (µm/s) | 53.5 ± 4.0 | 48.6 ± 1.8 |
| VCL (µm/s) | 111.3 ± 4.5 | 93.5 ± 2.4 |
| VAP (µm/s) | 64.7 ± 3.7 | 57.3 ± 1.9 |
| STR (%) | 80.8 ± 1.8* | 82.2 ± 0.5* |
| LIN (%) | 48.5 ± 1.9 | 52.0 ± 0.8 |
| ALH (µm) | 4.7 ± 0.2 | 4.1 ± 0.1 |
| BCF (Hz) | 28.9 ± 1.2 | 28.9 ± 0.4 |
| Progressive sperm (%) | 39.8 ± 5.8* | 33.4 ± 2.6* |
| Hyperactivation (%) | 10.5 ± 1.5* | 3.4 ± 0.5* |
Results are expressed as means ± standard error of the mean (SEM; n = 6). The results showed that 5 µM 17-AAG significantly inhibited human sperm hyperactivation (*P < 0.05). VSL straight line velocity; VCL curvilinear velocity; VAP average path velocity; STR straightness (VSL/VAP multiplied by 100); LIN linearity (VSL/VCL multiplied by 100); ALH amplitude of lateral head displacement; and BCF beat-cross frequency